Antihypertensive Effects of Drospirenone With 17β-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background— Drospirenone (DRSP) is a novel progestin with antimineralocorticoid activity that has been developed for hormone therapy in combination with 17β-estradiol (E2) in postmenopausal women. In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP). Methods and Results— The effects of 3 mg DRSP/1 mg E2 on clinic and 24-hour ambulatory BP as well as potassium homeostasis were evaluated in postmenopausal women with stage 1 hypertension (systolic, 140 to 159 and/or diastolic, 90 to 99 mm Hg) in a 12-week, multicenter, double-blind, randomized, placebo-controlled study. Clinic BPs were measured at baseline and at 2, 4, 6, 8, and 12 weeks of therapy, whereas potassium was measured at 2, 6, and 12 weeks of therapy. Ambulatory BP was performed in a substudy at baseline and at the end of the trial. In the intention-to-treat population of 213 women, the clinic BP was reduced significantly on DRSP/E2 (clinic BP, −14.1/−7.9 for DRSP/E2 versus −7.1/−4.3 mm Hg for placebo, P <0.0001). In the subgroup of 43 women with ambulatory BP monitoring, the 24-hour BP fell by −8.5/−4.2 mm Hg versus −1.8/−1.6 mm Hg on placebo ( P =0.002/0.07). There were no significant changes from baseline in potassium levels or in the incidence of hyperkalemia (≥5.5 meq/L) on DRSP/E2 compared with placebo. Conclusions— Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolic hypertension. This characteristic may lead to benefit for cardiovascular risk reduction in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationHulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationStaessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure
Oelkers, W. K. H. (1996) · Steroids · doi:10.1016/0039-128x(96)00007-4 · Cited by 333
Cited by
Menopause and cardiovascular disease: the evidence
Rosano, G. M. C., Vitale, C., Marazzi, G., & Volterrani, M. (2007) · Climacteric · doi:10.1080/13697130601114917 · Cited by 470
White, W. B., Hanes, V., Chauhan, V., & Pitt, B. (2006) · Hypertension · doi:10.1161/01.hyp.0000232179.60442.84 · Cited by 119
Self-citationCollins, P., Rosano, G., Casey, C., Daly, C., Gambacciani, M., Hadji, P., Kaaja, R., Mikkola, T., Palacios, S., Preston, R., et al. (2007) · Climacteric · doi:10.1080/13697130701755213 · Cited by 67
Self-citationBlood Pressure Effects of the Oral Contraceptive and Postmenopausal Hormone Therapies
Boldo, A., & White, W. B. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.01.008 · Cited by 54
Self-citationDifferent cardiovascular effects of progestins according to structure and activity
Nath, A., & Sitruk-Ware, R. (2009) · Climacteric · doi:10.1080/13697130902905757 · Cited by 46
Metadata
- Authors
- White, W. B., Pitt, B., Preston, R. A., & Hanes, V.
- Venue
- Circulation
- Published
- 2005-09-27
- Volume
- 112
- Issue
- 13
- Pages
- 1979-1984
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2127401950
- Cited by
- 108
- References
- 8
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihypertensive Effects of Drospirenone With 17β-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension. https://app.cochat.ai/papers/10.1161/circulationaha.104.501502
- The paper
- White, W. B., Pitt, B., Preston, R. A., & Hanes, V. (2005). Antihypertensive Effects of Drospirenone With 17β-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension. Circulation. https://doi.org/10.1161/circulationaha.104.501502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.